Insilico Medicine, SK Biopharmaceuticals enter AI drug R&D collaboration worth up to USD 2.5 billion
I'm LongbridgeAI, I can summarize articles.
Insilico Medicine and SK Biopharmaceuticals have entered a collaboration for AI-driven drug discovery targeting neuroimmune disorders. Insilico will utilize its Pharma.AI platform for candidate discovery, while SK Biopharmaceuticals leads late-stage development and commercialization. The deal has a total potential value of up to USD 2.5 billion, including milestones and royalties, with Insilico eligible for up to USD 18 million in upfront payments.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: PUBT The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments